What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Khavinson vascular tripeptide (Lys-Glu-Asp, KED)
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Vesugen inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
Vesugen is a Khavinson-class tripeptide bioregulator with the sequence Lys-Glu-Asp (KED), positioned within the Khavinson framework as the vascular endothelial regulatory peptide. The KED sequence is distinct from the tetrapeptide-family members (AEDG / AEDL / AEDP) in that it is a three-residue rather than four-residue peptide and includes a basic N-terminal lysine, both features shifting its biophysical profile from the AEDx tetrapeptide siblings. Vesugen is studied in research workflows examining vascular endothelial gene-expression programs, angiogenesis-related signaling, and cardiovascular tissue maintenance within the Khavinson bioregulator framework. PeptideXpo supplies Vesugen as a lyophilized 10 mg vial at ≥99.0% HPLC purity. As a tripeptide, Vesugen is simpler analytically than the tetrapeptide siblings, the molecular weight (392 g/mol theoretical) is distinct from the AEDx tetrapeptide family and mass-spec confirmation alone is generally sufficient for identity. Sequence verification by LC-MS/MS is available on request.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Khavinson bioregulator; CAS commonly not registered. Confirm KED sequence and identity per batch COA.
Frequently asked questions
Vesugen (KED, Lys-Glu-Asp) is a tripeptide, while the more commonly characterized Khavinson family members (Epitalon AEDG, Bronchogen AEDL, Cortagen AEDP) are tetrapeptides. The size difference produces biophysical and analytical differences: Vesugen at 392 g/mol is distinct in mass from the tetrapeptide family (390-432 g/mol), so mass spec alone is sufficient for identity disambiguation against the tetrapeptides. The N-terminal lysine also gives Vesugen a different charge profile than the AEDx tetrapeptides (which start with neutral alanine), affecting RP-HPLC retention time. Vesugen is positioned within the Khavinson framework as the vascular endothelial regulatory peptide, mechanistically and tissue-targeting-wise distinct from its cousin peptides.
Russian-school publications on Vesugen and similar vascular-targeting short peptides focus on age-related endothelial dysfunction and atherosclerosis-prevention research in animal models. The mechanism hypothesis within the Khavinson framework is that the KED tripeptide acts as a regulatory signal on endothelial gene-expression programs, supporting vascular homeostasis and counteracting age-related decline in endothelial-cell turnover. Reported readouts in published studies include modulation of endothelial-cell proliferation markers, vasodilation-relevant gene expression, and improvements in vascular-function metrics in aged-rodent models. As with the broader Khavinson framework, the evidence base is concentrated in Russian-language journals; Western independent replication is limited, and Vesugen should be treated as an investigational research tool rather than a validated vascular therapeutic.
Lyophilized Vesugen is stable at -20 °C protected from light for the standard 24-month re-test window. The KED sequence is short (3 residues) and the N-terminal lysine makes the molecule somewhat more soluble in aqueous media than the more hydrophobic AEDx tetrapeptides, reconstitution in isotonic saline or sterile water for injection produces a clean solution at typical 1-5 mg/mL working concentrations. The reconstituted solution should be split into single-use aliquots immediately and frozen at -20 °C; as with all short Khavinson peptides, freeze-thaw cycling is the dominant in-lab degradation pathway. The 10 mg standard fill supports 50-200 single-dose research preparations depending on the protocol-specified dose per administration.
Related peptides
